FDA 483 - Aspire Houston Fertility Institute - February 06, 2020

Aspire Fertility in Houston, TX was inspected from February 5-6, 2020, regarding its human reproductive tissue operations. The inspection revealed a significant lapse in donor screening procedures, specifically the failure to perform physical examinations for directed semen donors to screen for communicable disease agents. This indicates a potential risk related to the safety of human reproductive tissue.